Influence of CYP3A5*3 polymorphism and interaction between CYP3A5*3 and CYP3A4*1G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery

European Journal of Anaesthesiology

Volumn 28, Issue 4, 2011, Pages 245-250

  Zhang, Wei ^a   Yuan, Jing Jing ^a   Kan, Quan Cheng ^a   Zhang, Li Rong ^a   Chang, Yan Zi ^a   Wang, Zhong Yu ^a   Li, Zhi Song ^b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Analgesia; CYP3A; Fentanyl; Phenotype; Polymorphism

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; ATRACURIUM; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FENTANYL; GENOMIC DNA; MIDAZOLAM; PROPOFOL; REMIFENTANIL; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; NARCOTIC ANALGESIC AGENT;

ADULT; ANESTHESIA INDUCTION; ARTICLE; ARTIFICIAL VENTILATION; BLOOD SAMPLING; CHINESE; DRUG BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENERAL ANESTHESIA; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GYNECOLOGIC SURGERY; HUMAN; HYSTERECTOMY; INFUSION PUMP; MAJOR CLINICAL STUDY; MYOMECTOMY; NEUROMUSCULAR BLOCKING; PAIN ASSESSMENT; PATIENT CONTROLLED ANALGESIA; POLYMERASE CHAIN REACTION; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PAIN; POSTOPERATIVE PERIOD; PROTEIN PROTEIN INTERACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCORING SYSTEM; SURGICAL PATIENT; THERAPY EFFECT; VISUAL ANALOG SCALE; ANALYSIS OF VARIANCE; ASIAN; CHI SQUARE DISTRIBUTION; CHINA; ETHNOLOGY; GENETICS; METABOLISM; MIDDLE AGED; PHARMACOGENETICS; PHENOTYPE; TIME;

ADULT; ANALGESIA, PATIENT-CONTROLLED; ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; ASIAN CONTINENTAL ANCESTRY GROUP; CHI-SQUARE DISTRIBUTION; CHINA; CYTOCHROME P-450 CYP3A; FEMALE; FENTANYL; GENE FREQUENCY; GENOTYPE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; HYSTERECTOMY; MIDDLE AGED; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; TIME FACTORS; UTERINE MYOMECTOMY; YOUNG ADULT;

EID: 79953849214     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1097/EJA.0b013e3283438b39     Document Type: Article

References (25)

1. Davis JJ, Swenson JD, Hall RH, et al. Preoperative 'fentanyl challenge' as a tool to estimate postoperative opioid dosing in chronic opioid-consuming patients. Anesth Analg 2005; 101:389-395. (Pubitemid 41045219)
2. Guitton J, Buronfosse T, Desage M, et al. Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil. Biochem Pharmacol 1997; 53:1613-1619. (Pubitemid 27356090)
3. Feierman DE, Melinkov Z, Nanji AA. Induction of CYP3A by ethanol in multiple in vitro and in vivo models. Alcoholism 2003; 27:981-988. (Pubitemid 36759388)
4. Tateishi T, Krivoruk Y, Ueng YF, et al. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg 1996; 82:167-172. (Pubitemid 26017401)
5. Feierman DE, Lasker JM. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Drug Metab Dispos 1996; 24:932-939. (Pubitemid 26314543)
6. Labroo RB, Paine MF, Thummel KE, Kharasch ED. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: Implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 1997; 25:1072-1080. (Pubitemid 27396495)
7. Ibrahim AE, Feldman J, Karim A, Kharasch ED. Simultaneous assessment of drug interactions with low- and high-extraction opioids: Application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology 2003; 98:853-861. (Pubitemid 36373219)
8. Zhang W, Chang YZ, Kan QC, et al. CYP3A4*1G genetic polymorphism influences CYP3A activity and fentanyl analgesic effect in Chinese gynecologic patients. Eur J Clin Pharmacol 2010; 66:61-66.
9. Balram C, Zhou Q, Cheung YB, Lee EJD. CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol 2003; 59:123-126. (Pubitemid 36793724)
10. Hu YF, He J, Chen GL, et al. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 2005; 353:187-192. (Pubitemid 40215445)
11. Qiu XY, Jiao Z, Zhang M, et al. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol 2008; 64:1069-1084.
12. Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62:162-172. (Pubitemid 34680528)
13. Zhu B, Liu ZQ, Chen GL, et al. The distribution and gender difference of CYP3A activity in Chinese subjects. Br J Clin Pharmacol 2003; 55:264-269. (Pubitemid 36390756)
14. Woodhouse A, Mather LE. The minimum effective concentration of opioids: A revisitation with patient controlled analgesia fentanyl. Reg Anesth Pain Med 2000; 25:259-267. (Pubitemid 30337719)
15. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning a laboratory manual, 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory; 1989; pp. 16-19.
16. Kronbach T, Mathys D, Umenou M, et al. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989; 36:89-96. (Pubitemid 19191264)
17. Wandel C, Bocker R, Bohrer H, et al. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 1994; 73:658-661. (Pubitemid 24323498)
18. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-391. (Pubitemid 32268418)
19. Kharasch ED, Walker A, Isoherranen N, et al. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther 2007; 82:410-426. (Pubitemid 47414348)
20. Tomalik-Scharte D, Doroshyenko O, Kirchheiner J, et al. No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam. Eur J Clin Pharmacol 2008; 64:1033-1035.
21. Jin M, Gock SB, Jannetto PJ, et al. Pharmacogenomics as molecular autopsy for forensic toxicology: Genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J Anal Toxicol 2005; 29:590-598. (Pubitemid 41803344)
22. Macphee IA, Fredericks S, Mohamed M, et al. Tacrolimus pharmacogenetics: The CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation 2005; 79:499-502. (Pubitemid 40280186)
23. Hu YF, Qiu W, Liu ZQ, et al. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin Exp Pharmacol Physiol 2006; 33:1093109-1093118.
24. Chu XM, Hao HP, Wang GJ, et al. Influence of CYP3A5 genetic polymorphism on cyclosporine A metabolism and elimination in Chinese renal transplant recipients. Acta Pharmacol Sin 2006; 27:1504-1508.
25. Kivistö KT, Niemi M, Schaeffeler E, et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 2004; 14:523-525. (Pubitemid 39100004)